Scientists aim to smarter design dementia trials
NCT ID NCT05592678
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests new methods to improve how dementia clinical trials are run. Researchers want to see if a combined score of thinking and daily function can better measure treatment effects. They will also check if blood proteins can predict who responds to the Alzheimer's drug donepezil. About 200 people with mild cognitive impairment or Alzheimer's, aged 65-100, and their caregivers will take part.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ALZHEIMER'S DISEASE(AD) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Univeristy of Texas Health Science Center at San Antonio (UTHSCSA)
RECRUITINGSan Antonio, Texas, 78229-3900, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a simple questionnaire empower dementia caregivers after hospital stays?
- Can we predict chemo brain before it happens?
- Can a simple test predict Alzheimer's before symptoms worsen?
- Can a Voice-Based app map healthy brain aging across 80 years?
- A handful of blueberries a day: a new weapon against cognitive decline?
- Could sharing lived experiences ease the burden of dementia care?